MED-X Files Fourth IPO Amendment with 16.25 Million Shares and Still No Price

As seen on the 24/7 Wall St. homepage on November 17, 2026.

IPO TERMS REVISED
MED-X, INC. MXRX · Nasdaq
16,248,842 shares

Fourth amendment: 16.25 million shares, terms still unset

MED-X is back for a fourth time, still without a price, now putting 16.25 million shares in front of Nasdaq buyers with Maxim Group running the book. Each amendment resets the clock on a deal that has yet to set terms.

Continue ReadingShow less

MED-X has now filed four amendments to its Nasdaq IPO registration without ever setting a price range, a pattern that signals either ongoing negotiations with underwriter Maxim Group or unresolved demand questions that have kept the deal from moving forward.

The latest amendment puts 16,248,842 shares in front of potential buyers, giving investors a clearer sense of the deal's size even as the fundamental question of what those shares will cost remains unanswered.

Sponsored

Each new amendment restarts the regulatory clock under SEC rules, meaning the company must keep updating its filing before it can actually price and sell shares to the public. Four rounds of that process without reaching terms is an unusually prolonged runway for a deal of this type.

For anyone tracking this offering, no price range has been set after four attempts. Until MED-X sets terms, there is no deal to participate in, and the timeline for when that might happen is not disclosed in the filing.

Mentioned: MXRX